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OBJECTIVE — Theobjectiveofthisstudywastoevaluatetheassociationbetweenfootulcers
(DFU) and lower-extremity amputation (LEA) and chronic kidney disease (CKD) in patients
with diabetes.
RESARCH DESIGN AND METHODS — This was a retrospective cohort study of in-
dividuals enrolled between 2002 and 2006 who were aged 35 years, had a history of diabetes,
and were cared for in general practice. The physicians participated in The Health Information
Network of the U.K.
RESULTS — The presence of DFU or LEA and estimated glomerular ﬁltration rate (eGFR)
were evaluated in 90,617 individuals with a median time of observation of 2.4 years. Of these
individuals 378 had an LEA and 2,619 had a DFU. CKD (eGFR 60 ml/min per 1.73 m
2) was
noted in 23,350 (26%) individuals in our cohort. For the development of DFU compared with
our reference group (group 1 [eGFR 60 ml/min per 1.73 m
2]), the hazard ratio (HR) for group
2 (eGFR 30 and 60 ml/min per 1.73 m
2) was 1.85 (95% CI 1.71–2.01) and for group 3
(eGFR 30 ml/min per 1.73 m
2) was 3.92 (3.23–4.75) (all P  0.001). For LEA, the HR for
group 2 was 2.08 (1.68–2.58) and for group 3 was 7.71 (5.29–11.26) (all P  0.001).
CONCLUSIONS — Inthisobservationalstudy,thereisastrongassociationbetweenstageof
CKD and DFU or LEA that is probably not just related to the presence of peripheral arterial
disease. Individuals with even moderate CKD (eGFR 60 ml/min per 1.73 m
2) have an in-
creased risk for DFU and LEA.
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D
iabetic foot ulcer (DFU) and lower-
extremity amputation (LEA) are se-
verecomplicationsofolderindivid-
uals who develop diabetes. LEA is often
associated with a preexisting DFU. The
annual incidence of DFU among those
with diabetes is between 1.5 and 4%, and
foot problems are the most frequent rea-
sonthatindividualswithdiabetesarehos-
pitalized (1). The health care costs
associated with DFUs and LEAs are high.
In 1995, U.S. Medicare claims for DFUs
exceeded $1.4 billion (2). LEAs also have
aprofoundeffectonqualityoflifeandare
associated with increased health care
costs and an increased risk of mortality
(3–5). Nontraumatic LEAs are at least 15
times more prevalent in those with diabe-
tes than in those with any other concom-
itant medical illness (3,6). In the U.S.,
nearly 80,000 LEAs are performed for di-
abetic patients each year (7). The rate of
LEA, per the Centers for Disease Control
and Prevention and other sources, is
4–8 per 1,000 individuals hospitalized
with diabetes, which contrasts with a rate
of about 3 per 10,000 in the general pop-
ulation (7,8). Within 5 years of having an
LEAabout60%ofthosewithdiabeteswill
die(5).Asthenumberofindividualswith
diabetes increases, so probably will the
number of individuals with an LEA.
Diabetes is a strong risk factor for
chronic kidney disease (CKD). Surpris-
ingly little has been published on the
overall occurrence of DFU and LEA
among those with CKD and diabetes.
WithrespecttoCKDandLEA,moststud-
ies have focused on end-stage renal dis-
ease (ESRD) and have often noted an
association with peripheral arterial dis-
ease (PAD), thereby claiming a common
atherosclerotic cause. For example, with
respect to ESRD, regardless of the con-
comitant presence of diabetes, studies
have shown various but markedly in-
creased rates of LEA in that 5% and as
manyas50%willhaveanamputation(9–
11). Furthermore, the risk of LEA is at
least two to six times greater among those
with both diabetes and CKD than among
those with diabetes alone (9,10). PAD is
thought to be the mechanistic link be-
tween CKD and LEA (9–11). A recent
studyusingdatafromtheNationalHealth
and Nutrition Examination Survey dem-
onstrated the importance of the relation-
ship between CKD and PAD. Among
those with a creatinine clearance of 60
ml/min per 1.73 m
2 who do not have
ESRD,therewasa2.5timesincreasedrisk
of PAD compared with the risk for those
without CKD (11). An analysis of partic-
ipants in the Heart and Estrogen/
Progestin Replacement Study also
showed that women with CKD were be-
tween 1.63 and 3.24 times more likely to
have PAD. In this study, the likelihood of
PAD increased with decreasing creatinine
clearance (12). Finally, although the on-
set of LEA has been associated with ESRD
andCKD,studieshavetendedtoassociate
the onset of LEA with clinically apparent
PAD, but none have evaluated DFU
among those with CKD or the onset of
LEA among those with CKD but without
clinically apparent PAD.
WehypothesizedthattheriskofDFU
and LEA is associated with worsening
CKD.Totestthishypothesisweevaluated
the association between DFU and LEA
and CKD in a large population-based co-
hort of individuals with diabetes. CKD
was determined using a priori deﬁned cut
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rate (eGFR). We also evaluated whether
associations between DFU and LEA and
CKD occurred in the absence of clinically
apparent PAD.
RESEARCH DESIGN AND
METHODS— We conducted a retro-
spective cohort study of individuals with
diabetes who were treated in general
medical practices that participate with
The Health Information Network (THIN)
data system. This study was reviewed by
the Institutional Review Board of the Uni-
versity of Pennsylvania.
THIN was created in 2002 and in-
cludes data from 300 physician practices
in England and Wales. THIN subjects are
broadly representative of the U.K. popu-
lationandaresimilarinage,sex,andgeo-
graphic characteristics (13). THIN
includesrecordson4.78millionpatients,
of whom 2.26 million are currently active
participants. The patient population in
THIN is stable with only 3% of patients
being lost per year attributable to leaving
a practice or death. The database for
THIN, contains information on medical
diagnoses (acute and chronic), as well as
free text on these conditions. THIN also
includes laboratory values, which are
electronically captured, and some aspects
of the physical examination, as well as
hospitalizations, consultations, and pre-
scription medications, which are elec-
tronicallytransferredtoTHIN.Theability
to ascertain the diagnosis of diabetes has
been previously investigated by National





All subjects enrolled in this cohort had at
leasttwodatabaserecordsfordiabetesbe-
tween January 2002 and January 2005
andwererequiredtobeatleast35yearsof
age by January 2002.
The primary exposure variable was
eGFR. The eGFR was estimated using the
Modiﬁcation of Diet in Renal Disease
equation (15). Our estimate did not in-
clude a mathematical expression for eth-
nicity/race,whichisacommonpracticein
theU.K.(15).Thisomissionwasalsonec-
essary because race/ethnicity is not re-
corded in THIN. We also explored via
sensitivity analyses whether the inability
to adjust for race/ethnicity would have
had an affect on our results (see below).
CKD was deﬁned on the basis of
eGFR and categorized into three levels
corresponding to the U.S. National Kid-
ney Foundation staging scheme for CKD.
These three categories were deﬁned by
the National Kidney Foundation cut
points between stage II and stage III CKD
as well as between stage III and stage IV
(60, 30 to 60, and 30 ml/min per
1.73 m
2, respectively) (15).
Outcomes were determined sepa-
rately in each study subject for incident
DFU and incident LEA on the basis of the
computerized medical records. There-
fore, DFUs in this study were chronic or
severe enough to require a patient to seek
medical care and may not represent all
woundsonthefeetofthosewithdiabetes.
For a DFU to be considered incident, the
subject must have had no report of a DFU
for at least 6 months before the database
record of the eGFR. For a LEA to be con-
sidered incident, it needed to be ﬁrst
coded after the database record of the
eGFR. If the subject had a prior LEA, a
new one must have occurred on the con-
tralateral leg or a previous LEA must have
been converted from a minor to major
(transtibial) amputation. Because of the
potential for recording error, it was not
possible to identify a new minor amputa-
tion on a foot with a previous minor am-
putation (e.g., the amputation of the ﬁfth
digit after a previous amputation of the
ﬁrst). If an observed DFU or LEA did not
meet these criteria it was categorized as
“history of.”
In 2002, a series of performance pro-
grams were established and became
mandatoryby2003.Theserequireddocu-
mentationandassessmentsbythegeneral
practitioner at least every 15 months of
lower-limb pulses, neuropathy (usually
recorded as a failure to perceive 10 g of
monoﬁlament pressure), A1C, cigarette
use, and serum creatinine in those pa-
tients with diabetes. These assessments
were used as confounders in our study.
However, a confounder must be associ-
ated with the risk factor of interest (i.e.,
CKD) and the outcome (DFU or LEA). It
should not be on the causal pathway be-
tween the risk factor and the outcome.
Our confounders also included subject
age at the time of entering our cohort,
duration of diabetes as noted in the med-
ical record, practice site, diagnosis of his-
tory of myocardial infarction (myocardial
infarction or unstable angina), sex, and
history of hypertension. A subject was as-
sumed to have PAD if he or she had an
absence of pulses of both lower extremi-
ties (screening test frequently used in
U.K.clinicalpracticeandepidemiological
studies) or had a medical diagnosis con-
sistent with lower-extremity atheroscle-
rotic disease (16). It is possible that this
diagnosis of PAD lacks validity and there-
fore could result in an underestimate of
the true association between CKD and
LEA/DFU.
Statistical analysis
Deﬁnition of person-time. Our analysis
was based on person-year estimates. Per-
son-timewasestimatedfromthedatabase
date for the ﬁrst eGFR after 2002 until
either an outcome occurred (LEA and
DFU separately), the study subject died,
the study subject left the practice, or the
last transaction date in the database.
Multivariable analysis: explanatory
models. Descriptive statistics are pre-
sented by CKD categories and confound-
ers. The unadjusted hazard ratio (HR) of
the association between our CKD catego-
ries and DFU or LEA with 95% CI was
determined using proportional hazards
regression analysis. Individuals with
ESRD were excluded from these analyses.
All estimates were calculated for the full
sample and separately for both those with
and those without clinical history of PAD
(i.e., interaction). The ﬁnal multivariable
models (adjusted models) were devel-
oped by using variables deemed clinically
important for LEA and DFU and any vari-
able that changed the effect estimate by
15%. Proportional hazards models
were used, and the HRs are reported with
95% CIs. The ﬁt of the models was as-
sessed visually using Cox-Snell residuals
and by graphic display.
Sensitivity analyses were conducted
by reestimating the eGFR using the math-
ematical expression for African descent
by assuming that all subjects were of Af-
rican descent, by assuming that only
those in the most severe CKD class (i.e.,
those with eGFR 30 ml/min per 1.73
m
2) were of African descent, and by re-
petitive random sampling of 1% of the
population and reclassifying them as if
they were of African descent (1% is the
U.K.censusestimateofAfricanethnicity).
We also conducted analyses excluding
anyone with a past history of DFU or LEA
just in case those with a past history truly
did not have a new DFU or LEA after our
measured eGFR. All statistical analyses
were performed using Stata 9.2 (Stata
Corporation, College Station, TX).
RESULTS— There were 125,933 in-
dividuals identiﬁed with diabetes be-
CKD and foot ulcer or amputation
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THIN who were at least 35 years of age
andwhohadatleasttwovisits.Atthestart
of our period of observation, the average
age was 62.9 years (95% CI 62.8–63.0)
andthemedianagewas64.6years(52.6–
82.6).Womenrepresented53%(66,928)
of our cohort. Our subjects, after a docu-
mented eGFR, were followed for about
200,675 person-years of time between
January 2002 and July 2005. The average
time of follow-up was 2.2 years, and the
median time was 2.4 years. During this
time, 378 individuals had an LEA and
2,619 individuals had a DFU. Before en-
try into our cohort 3,491 subjects had a
diagnosisofDFUand768hadanLEA.Of
those in our cohort who needed an am-
putation, 70 (18%) had a previous minor
or contralateral LEA and 126 (33%) had a
previous DFU 6 months before their
entry into our cohort. Of those in our
cohort who developed a DFU, 569 (22%)
had a previous DFU before 6 months
prior to entry into our cohort and 138
(5%) had a previous LEA. CKD (eGFR
60 ml/min per 1.73 m
2) was noted in
23,350 (26%) of our cohort. PAD was
noted in 10,449 (12%) subjects. In ad-
dition, several other factors were associ-
ated with the development of DFU or
LEA, such as hyperglycemia, peripheral
neuropathy, hypertension, and history
of myocardial infarction (Table 1). eGFR
could be determined in 90,617 individu-
als (72% of the total).
Development of a DFU was associ-
ated with progressive CKD and many of
our other variables (Tables 1 and 2).
Compared with our reference group
(group 1 [eGFR 60 ml/min per 1.73
m
2]) the HR for group 2 (eGFR 30 and
Table 1—Fully adjusted HRs (95% CI) for the onset of a new foot ulcer or LEA
Variable Foot ulcer LEA
Prior foot ulcer 7.85 (7.16–8.62)* 13.06 (10.55–16.18)*
Prior amputation 8.00 (6.74–9.49)* 31.03 (23.93–40.23)*
Smoking
0 per day Ref Ref
1–15 per day 0.94 (0.84–1.05) 1.16 (0.88–1.53)
15 per day 0.97 (0.85–1.11) 0.62 (0.40–0.96)
Age by category
35–40 years Ref Ref
40–50 years 1.18 (0.92–1.49) 1.41 (0.71–2.89)
50–60 years 1.26 (1.02–1.56) 1.81 (0.98–3.36)
60–70 years 1.56 (1.27–1.92) 2.12 (1.16–3.85)
70 years 2.42 (1.98–2.96)* 2.80 (1.56–5.03)*
A1C by category
7.0% Ref Ref
7.0% and 9.0% 1.15 (1.05–1.26) 1.80 (1.38–2.35)
9.0% 1.66 (1.50–1.83)* 2.77 (2.10–3.64)*
Sex (women Ref) 0.98 (0.91–1.06) 0.50 (0.40–0.62)*
History of lower-extremity PAD 3.80 (3.51–4.12)* 12.00 (9.74–14.77)*
Loss of neurosensation 2.17 (1.88–2.51)* 2.34 (1.62,3.38)*
History of hypertension 1.17 (1.08,1.27)* 1.42 (1.15–1.75)*
History of myocardial ischemia 1.46 (1.35–1.59)* 1.63 (1.31–2.02)*
Duration of diabetes (years) 1.03 (1.03–1.04) 1.04 (1.04–1.05)
Mean arterial pressure 0.99 (0.99–1.00) 1.00 (0.99–1.01)
ESRD 6.12 (3.54–10.55)* 15.66 (6.48–37.86)*
P value, compared with reference (Ref)or, if categories are presented, as test for trend, *P  0.001.
Table 2—HRs (95% CI) of foot ulcer and LEA for the full dataset and for foot ulcer and LEA
A. Full dataset Foot ulcer Foot ulcer adjusted LEA
LEA adjusted (includes
an interaction term for PAD)
CKD (eGFR)
60 ml/min per 1.73 m
2 Ref Ref Ref Ref
30 to 60 ml/min per 1.73 m
2 1.85 (1.71–2.01) 1.51 (1.38–1.66) 2.08 (1.68–2.58) 2.28 (1.54–3.36)
30 ml/min per 1.73 m
2 3.92 (3.23–4.75) 3.22 (2.60–4.00) 7.71 (5.29–1.26) 8.05 (4.23–7.01)
B. Foot ulcer Foot ulcer without PAD Foot ulcer without
PAD adjusted
Foot ulcer with PAD Foot ulcer with PAD adjusted
CKD (eGFR)
60 ml/min per 1.73 m
2 Ref Ref Ref Ref
30 to 60 ml/min per 1.73 m
2 1.68 (1.51–1.86) 1.41 (1.24,1.58) 1.44 (1.26,1.65) 1.38 (1.18–1.60)
30 ml/min per 1.73 m
2 3.86 (3.00–4.98) 3.32 (2.55–4.33) 2.10 (1.56,2.84) 2.04 (1.49–2.79)
C. LEA LEA without PAD LEA without
PAD adjusted
LEA with PAD LEA with PAD adjusted
CKD (eGFR)
60 ml/min per 1.73 m
2 Ref Ref Ref Ref
30 to 60 ml/min per 1.73 m
2 1.82 (1.28–2.60) 2.05 (1.37–3.07) 1.31 (1.00–1.72)* 1.60 (1.19–2.16)
30 ml/min per 1.73 m
2 6.96 (3.50–13.83) 7.80 (3.82–15.90) 2.90 (1.76,4.76) 3.33 (1.93–5.77)
Adjusted and unadjusted results are shown. Parts B and C include results in the presence or absence of peripheral arterial disease. Compared with reference (Ref)
or as a test for trend, all P values 0.001 unless *P  0.05.
Margolis, Hofstad, and Feldman
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2) was 1.85 (95%
CI 1.71–2.01) and for group 3 (eGFR
30 ml/min per 1.73 m
2) was 3.92
(3.23–4.75) (all P values  0.001). The
fully adjusted associations between DFU
and CKD were 1.51 (1.38–1.66) for
group 2 and 3.22 (2.60–4.00) for group
3,bothversusgroup1(allP0.001).An
interaction due to PAD was also present
(Pinteraction  0.08 for group 2; Pinteraction
 0.003 for group 3), and, as a conse-
quence, our CKD effect estimates are re-
ported for those with and without PAD
(Table 2).
Theneedforanamputationwasasso-
ciated with progressive CKD and many of
our other variables (Tables 1 and 2).
Compared with the reference group
(group 1), the HR for group 2 was 2.08
(95% CI 1.68–2.58) and for group 3 was
7.71(5.29–11.26)(P0.001).Ourfully
adjusted association between LEA and
CKD was 2.18 (1.70–2.78) for group 2
and 7.09 (4.57–11.00) for group 3, re-
spectively (all P  0.001). These esti-
mates were inﬂuenced primarily by an
interaction due to PAD (Pinteraction  0.07
forgroup2;Pinteraction0.04forgroup3)
(Table 2). All CKD effect estimates are
therefore reported for those with and
without PAD (Table 2).
As noted above, 35,316 (28%) of
those in THIN did not have the full data
necessaryforacalculationofeGFR.There
weremanyattributesthatweresimilarbe-
tween those in our cohort and those who
did not have data allowing an estimate of
eGFR. For example, for our main con-
founders, the mean age was 63.9 years
and 51% were women. When their full
medical record and not just data obtained
after 2002 was evaluated, 5% had evi-
dence of a foot ulcer at some time in their
medical record versus 4% for our cohort
and 1% had a record of an amputation
versus 1% for our cohort, 26% used insu-
lin versus 23% of our cohort, and 0.9%
had a history of ESRD versus 0.8% of our
cohort.
We conducted several sensitivity
analyses. The Modiﬁcation of Diet in Re-
nal Disease estimation includes a term for
Africanethnicity(15).Thistermincreases
the eGFR estimate by 20%. This vari-
able is frequently not recommended for
use in the calculation of eGFR in the U.K.
(15). About 1% of the U.K. population is
African.Wewerenotabletomeasureeth-
nicity, but we did create sensitivity anal-
ysis to evaluate whether our inability to
measure African ethnicity might have af-
fected our results. First, we randomly as-
sumed that 1–5% of our population
might be African. This did not apprecia-
bly affect our point estimates as reported
inTable2.Nextweassumedthatallofthe
individuals in the worst CKD category
were African. This had minimal effect on
the estimation of our point estimates. For
example, this resulted in point estimates
of 2.08 (95% CI 1.68–2.56) and 7.18
(4.37–11.78) for CKD and LEA, respec-
tively. Finally, we conducted an “unmea-
sured confounders” sensitivity analysis
and were not able to eliminate the associ-
ationofCKDwithDFUorLEAusingpre-
viously demonstrated effect estimates for
race/ethnicity.
CONCLUSIONS— Several authors
have noted a relationship between ESRD
and LEA. Within one of the largest stud-
ied cohorts of diabetic subjects who have
eGFR measurements, we have shown a
strong association, not just with ESRD,
but between the severity of CKD and the
onset of both DFU and LEA among those
with diabetes. Whereas this association is
greatest for those with the most severe
CKD, even those with less severe CKD
wereapproximatelytwotimesmorelikely
to develop a foot ulcer or undergo an LEA
than those with minimal to no impair-
ment (Table 2). This association was
present among those without clinically
apparent PAD. To conﬁrm the appropri-
ateness of our database and analysis, we
were also able to show, as expected, an
association between DFU or LEA and hy-
perglycemia, PAD, peripheral neuropa-
thy, hypertension, history of myocardial
infarction, age, previous history of DFU,
previous history of LEA, and ESRD.
Traditionally, the complications of
diabeteshavebeendividedintothosedue
to microvascular disease and those due to
macrovascular disease. Microvascular
complications include retinopathy, ne-
phropathy, and peripheral neuropathy.
Macrovascular diseases include coronary
heart disease, stroke, and PAD/clau-
dication. Exactly where DFUs and LEA ﬁt
intothisschemeisnotalwaysclear.Many
ofthesediabeticindividualshaveneurop-
athy and/or PAD. This might imply that
these are both macro- and microvascular
illnesses.
In our study we were able to explore
DFUandLEAinindividualswithorwith-
outclinicallyapparentPAD.Wewereable
to show a relationship between these out-
comes and progressive CKD. Although
there may be many potential mechanisms
used to explain the onset of CKD, DFU,
and LEA in those with diabetes, it is fas-
cinating to note that structurally in many
ways the onset of CKD many be similar to
the onset of DFU and/or LEA. As a conse-
quence of hyperglycemia different cell
types,suchasmesangialcells,whichhave
some phenotypic properties similar to
those of ﬁbroblasts, and podocytes, are
damaged (17). These cells are damaged
from hyperglycemia, but the damage is
also physically attributable to the trauma
induced by hypertension (18). Unlike re-
nal cells, the cells of the dermis may be
replenished from neighboring cells, tran-
sient amplifying cells local to the wound,
and bone marrow–derived cells. One
mighthypothesizethattheonsetandpro-
gression of CKD might serve as an early
marker(notactuallyariskfactor)because
severe damage occurs ﬁrst in the kidney
(cells most sensitive to hyperglycemia
that cannot replenish) and then later in
theskin,whichcanreplenish,resultingin
the onset of DFU and ultimately LEA.
In the setting of a DFU, local trauma
(e.g., walking, poor-ﬁtting shoes, plantar
contact with hard objects, and others) is
often thought to initiate foot ulcers (19).
Interestingly, in a recent secondary anal-
ysis of a randomized clinical trial of foot-
wear, which looked only at one form of
trauma that was due to daily weight bear-
ing, the authors noted that by itself this
formoftraumawasnotdirectlyassociated
with DFUs (19,20). There may be many
explanations for this result. Our preced-
ing hypothesis might help to explain this
ﬁnding and to explain why trauma does
not cause wounds in everyone with dia-
betes; i.e., before trauma results in a clin-
ically signiﬁcant wound, an individual’s
ability to repair must ﬁrst be altered. This
explanationdoesnotdiminishtheimpor-
tance of trauma as the likely cause of the
initial insult that results in a DFU or LEA,
butitmaybethatCKD,neuropathy,PAD,
andmanyothercomplicationsofdiabetes
are on the same causal pathway related to
the progressive inability to repair. Statis-
tically, if this is true, then in our study we
underestimated the magnitude of the as-
sociations that we report by adjusting our
models for PAD, neuropathy, and so on.
As an alternative explanation, circulating
factors that directly affect wound repair
and ultimately are responsible for LEA
and DFU, may exist as a consequence of
progressive CKD.
There are a number of important po-
tential limitations to our study. With re-
spect to selection bias we did not have
eGFR measurements for all subjects in
CKD and foot ulcer or amputation
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ners preferentially measured creatinine in
those with more severe renal disease who
were most likely to develop a DFU or un-
dergo an LEA. This is unlikely because
this association is not well known. In ad-
dition, the completion of the required ex-
aminations is a performance criterion of
the general practitioners, which is linked
to their pay (www.nhsemployers.org/
pay-conditions/index.cfm) (21). A re-
cently published audit revealed that 96%
complied (21). Our study began in 2002,
before mandatory compliance and eGFR
measurements were available for 72%
of subjects. After 2003 about 92% of sub-
jects had eGFR measurements. It is also
possible that general practitioners failed
to diagnose or record our outcomes. If
thisweretruethenourresultswouldhave
been biased to the null unless the general
practitioners a priori decided that an as-
sociation between eGFR, a value requir-
ing calculation, and our outcomes
existed.Therecouldalsobeconcernsthat
dataarenotalwayscollectedintherecord
for THIN. It is important to realize that
per agreement with the company that or-
ganizes THIN, the record for THIN is the
general practitioner’s only medical
record. We could have mis-speciﬁed the
degree of CKD because we did not know
thesubjects’ethnicity/race.Ethnicity/race
is an unmeasured confounder in our
study. We were able to conduct several
sensitivityanalysesandfoundthatourin-
abilitytodeterminerace/ethnicitywasnot
likely to have inﬂuenced our measure-
ment of eGFR. Further, Abbott et al. (22)
did note various rates of foot complica-
tions and PAD and DFU in ethnic groups.
However, these authors concluded that
variable rates of PAD and neuropathy at
leastpartiallyexplainedthedifferentrates
of LEA and DFU in these ethnic groups.
We did adjust for PAD and neuropathy in
ourstudytoo.Itispossiblethatimportant
assessments such as PAD and neuropathy
weremeasuredwitherror.However,asin
other studies they were measured by gen-
eral practitioners in their practices,
thereby making these assessments gener-
alizable to other general practice settings
and even to other studies such as that of
Abbott et al. Because we know of no rea-
son that the accuracy of their measure-
ment would have been inﬂuenced by the
general practitioner’s knowledge of eGFR
(a calculated blood test), this error is
probably “nondifferential,” meaning that
any bias due to this error should have re-
sulted in an underestimate in the associa-
tion between CKD and LEA or DFU.
In summary, we have demonstrated a
strong association between CKD and
DFU or LEA among a population-based
sample of individuals with diabetes who
are cared for by general practitioners in
the U.K. It is important to note that dem-
onstrating an association is not the same
as showing causation, which often re-
quires an experimental design such as a
randomized clinical trial and the demon-
stration of a common mechanism that
causesCKDandfailureoftheskintoheal.
On the basis of our study, it is likely that
CKD and DFU or LEA among those with
diabetes are associated more tightly then
wasrecognizedpreviously.Clinically,our
ﬁndings are important in that we have
shown an association between even in-
dividuals with moderate CKD (eGFR
60 ml/min per 1.73m
2) and an in-
creased risk for the onset of DFU and
ultimately amputation.
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